文献速递间质性肺疾病

家庭监测提高特发性肺纤维化终点评估效率

Home monitoring improves endpoint efficiency in idiopathic pulmonary fibrosis.
PubMed 文献 · Eur Respir J · 2017-07-05

该研究纳入25例特发性肺纤维化(IPF)患者,每周使用手持肺量计和自填呼吸困难问卷进行家庭监测,评估用力肺活量(FVC)和呼吸困难的可靠性、可行性及分析影响。结果显示24周平均依从性超过90%,每周FVC评估较仅基线和24周测量可提高精确度和检验效能,模拟24周临床试验所需样本量从3840例降至951例。

要点

  • IPF患者每周家庭监测FVC和呼吸困难依从性高,24周平均依从性超过90%。
  • 每周家庭FVC评估较传统诊室间隔测量提高终点评估精确度和检验效能。
  • 模拟24周临床试验以FVC为主要终点,家庭每周肺量计需951例,诊室仅第1和24周测量需3840例。

核心结论

  • 家庭监测可提高IPF临床试验终点评估的精确度,从而提升治疗试验的效率。

研究设计与样本

  • 研究纳入25例IPF患者,每周使用移动手持肺量计和自填呼吸困难问卷进行家庭评估。
  • 基于每周FVC和呼吸困难变异性,模拟假设24周临床试验中传统诊室间隔测量与移动每周评估的样本量需求。

主要发现

  • 24周内每周评估的平均依从性大于90%。
  • 与仅用基线和24周测量评估变化相比,每周FVC评估提高了精确度和检验效能。
  • 模拟24周临床试验以FVC为主要终点,每周家庭肺量计需951例,而仅第1和24周诊室肺量计测量需3840例。
  • 重复测量减少临床试验样本量的能力受数据相关结构影响。

关键数值与推荐

  • 24周平均依从性大于90%。
  • 模拟24周临床试验以FVC为主要终点:每周家庭肺量计需951例,仅第1和24周诊室肺量计测量需3840例。

临床怎么用

  • 在IPF临床试验中可考虑采用每周家庭FVC监测作为终点评估方式,以提高精确度和减少样本量。
  • 家庭监测方案需关注患者依从性,本研究显示24周平均依从性大于90%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The objective of this study was to investigate the reliability, feasibility and analytical impact of home-based measurement of forced vital capacity (FVC) and dyspnoea as clinical endpoints in idiopathic pulmonary fibrosis (IPF).Patients with IPF performed weekly home-based assessment of FVC and dyspnoea using a mobile hand-held spirometer and self-administered dyspnoea questionnaires. Weekly variability in FVC and dyspnoea was estimated, and sample sizes were simulated for a hypothetical 24-week clinical trial using either traditional office-based interval measurement or mobile weekly assessment.In total, 25 patients were enrolled. Mean adherence to weekly assessments over 24 weeks was greater than 90%. Compared with change assessment using baseline and 24-week measurements only, weekly assessment of FVC resulted in enhanced precision and power. For example, a hypothetical 24-week clinical trial with FVC as the primary endpoint would require 951 patients using weekly home spirometry compared with 3840 patients using office spirometry measures at weeks 1 and 24 only. The ability of repeated measures to reduce clinical trial sample size was influenced by the correlation structure of the data.Home monitoring can improve the precision of endpoint assessments, allowing for greater efficiency in clinical trials of therapeutics for IPF.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Johannson KA, Vittinghoff E, Morisset J, et al. Home monitoring improves endpoint efficiency in idiopathic pulmonary fibrosis. Eur Respir J. 2017. PMID: 28679608. doi:10.1183/13993003.02406-2016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。